Compare · PACB vs QSI
PACB vs QSI
Side-by-side comparison of Pacific Biosciences of California Inc. (PACB) and Quantum-Si Incorporated (QSI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Industrials sector. PACB focuses on Biotechnology: Laboratory Analytical Instruments, while QSI focuses on Industrial Machinery/Components.
- PACB is the larger of the two at $613.3M, about 2.4x QSI ($252.7M).
- PACB has been more active in the news (10 items in the past 4 weeks vs 4 for QSI).
- PACB has more recent analyst coverage (25 ratings vs 4 for QSI).
- Company
- Pacific Biosciences of California Inc.
- Quantum-Si Incorporated
- Price
- -
- -
- Market cap
- $613.3M
- $252.7M
- 1M return
- -
- -12.64%
- 1Y return
- -
- -16.48%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2010
- 2020
- News (4w)
- 10
- 4
- Recent ratings
- 25
- 4
Pacific Biosciences of California Inc.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a collaboration with Invitae Corporation to develop ultra-high-throughput clinical whole genome sequencing platform; and a research collaboration with Rady Children's Institute for Genomic Medicine for whole genome sequencing platform. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Quantum-Si Incorporated
Quantum-Si incorporated operates first next-generation protein sequencing and genomics platform for healthcare industries. It offers a single molecule detection solution to decode the molecules of life, including sample preparation, single molecule, massively parallel, and protein identification. The company's technology has the applications in proteomics, single cell, transcriptomics, genomics, metabolomics, and drug testing and screening fields. The company is based in Guilford, Connecticut. Quantum-Si incorporated is a subsidiary of 4Catalyzer Corporation.
Latest PACB
- New insider Meyer William claimed ownership of 44,000 shares (SEC Form 3)
- Pacific Biosciences of California Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 424B5 filed by Pacific Biosciences of California Inc.
- SEC Form SCHEDULE 13G filed by Pacific Biosciences of California Inc.
- SEC Form SCHEDULE 13G filed by Pacific Biosciences of California Inc.
- SEC Form 10-Q filed by Pacific Biosciences of California Inc.
- Pacific Biosciences of California Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits
- PacBio Announces Third Quarter 2026 Financial Results
- PacBio to Participate in Upcoming Investor Conferences
- PacBio and Verily Health Announce Multi-Year Strategic Collaboration to Scale Long-Read Genomics for Biomedical AI
Latest QSI
- Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 10-Q filed by Quantum-Si Incorporated
- Quantum-Si Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Quantum-Si Reports Third Quarter 2026 Financial Results and Provides Business Update
- Quantum-Si to Provide a Business Update and Report Third Quarter 2026 Financial Results on November 5, 2026
- SEC Form 8-K filed by Quantum-Si Incorporated
- Quantum-Si Regains Compliance with Nasdaq Minimum Bid Price Requirement
- SEC Form 8-K filed by Quantum-Si Incorporated
- Quantum-Si Demonstrates Detection of 19 Amino Acids in Proteus™ Development Program
- Quantum-Si Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits